This study is exploring a potential new treatment for a type of pancreatic cancer that can't be entirely removed by surgery. The treatment involves a drug called **TTI-101**, which is thought to help improve the effects of *stereotactic body radiation therapy* (SBRT). SBRT is a special type of radiation therapy that targets the tumor more precisely. Researchers believe using TTI-101 with SBRT might help patients live longer without the cancer getting worse. Patients must be at least 18 years old and have completed some chemotherapy before joining. The study's goal is to see if this combination is safe and improves outcomes over two years. Participants must be able to swallow pills and follow other health guidelines. **Key Points:** - Participants need to be available for several visits and follow-ups. - The study lasts for about two years, with frequent monitoring. - Participants will receive free treatment and possible compensation for their time and travel. This study is not for those with recent heart issues, other cancers, or certain infections. Eligible participants will be asked to sign a consent form agreeing to the study's terms.